TP53 and T-cell non-Hodgkin lymphoma: We did not observe the proliferative advantage for the cells expressing RHOA-G17V that other authors reported when overexpressing RHOA-G17V in normal T cells [19] or T-cell lymphoma [13] due to the fact that we analyzed neoplastic cells with a TP53 aberration.